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Type II and type V CRISPR effector nucleases from 
a structural biologist’s perspective
ABSTRACT
The type II and type V CRISPR effector nucleases Cas9 and Cpf1 are “universal” DNA endo-nucleases, which can be programmed by an appropriate crRNA or sgRNA strand to cleave 
almost any DNA duplex at a preselected position (constrained only by short, so-called PAMs). In 
this review, we briefly introduce CRISPR bacterial adaptive immunity as the biological context 
in which Cas9 and Cpf1 proteins operate, and then present the structural insights that have been 
obtained in the last two or three years that illustrate the mode of operation of these proteins. We 
describe the R-loop structures at the core of the Cas9 and Cpf1 complexes, and the structure of the 
5’- or 3’-handles that help anchor the nucleic acid complexes to the proteins in a manner that is 
independent of the target sequence. Next, we describe the molecular architecture of the Cas9 and 
Cpf1 proteins. We illustrate how Cas9 and Cpf1 proteins scan double stranded DNA for so-called 
protospacer associated motifs (PAMs), we explain how the phosphate loop (PLL) and basic helix 
(BH) promote the separation of target and non-target DNA strands and the formation of hybrids 
between crRNA or sgRNA and the target strand of DNA. We also describe the current under-
standing of the catalytic mechanisms of RuvC and HNH domains, and a possible, but still very 
uncertain catalytic role of the Nuc domain. At the end of the review, we briefly summarize key 
developments that have initiated the field of genomic engineering using Cas9 or Cpf1 nucleases.
INTERACTIONS OF BACTERIA WITH THEIR PATHOGENS
Bacteria defend themselves against nucleic acids from invading phages or conju-
gating plasmids at multiple levels [1]. Immunity can result from interference with 
various steps of phage infection of plasmid conjugation, and is mechanistically di-
verse. Endonucleases play an important role. Generic immunity of bacteria against 
invading DNA is typically based on a distinction between self- and non-self that 
relies on the modification status of the DNA [2]. In the prototypical situation, bacte-
ria acquire a restriction modification system consisting of a DNA methyltransferase 
and an endonuclease of matching or slightly narrower specificity, which is inhibited 
by the methylation. The methyltransferase protects host DNA against endonuclease 
cleavage. Invading DNA lacks the modification, and is cleaved by the endonuclease 
before it is protected by the methyltransferase. Propagation of phages or plasmids 
in hosts that protect their own DNA by methylation can endow invading DNA with 
the hallmarks of “self”. This has in some cases prompted a reversal of the role of 
methylation, now treated as a hallmark of non-self. Restriction systems for the de-
fense against modified DNA do not require a protective methyltransferase for the 
host, and rely on endonucleases that only cleave modified DNA [3]. Either way, 
immunity is generic, and does not depend on a prior interaction between host and 
pathogen. In some sense, this type of bacterial immunity is functionally analogous 
to the “innate” immunity of vertebrates against their pathogens.
CRISPR ADAPTIVE, PATHOGEN SPECIFIC IMMUNITY
Adaptive, pathogen specific immunity of bacteria against invading nucleic acids 
has recently moved into the focus of interest. It is not based on the modification 
status of DNA, but instead relies on identification of pathogens based on the storage 
of their “fingerprints” in the form of a “blacklist” centrally encoded in the bacterial 
genome [4] (Fig. 1). The “blacklist” is a CRISPR cluster that contains short stretches 
of pathogen sequence separated by repeats. Prior to the elucidation of their biolog-
ical role, the short stretches of pathogen sequence were termed “spacers”. This ter-
minology has remained in place, even though with hindsight it is now clear that the 
“spacers” actually carry the important information in CRISPR clusters, whereas the 
repeats just serve to “separate” spacers representing different pathogens [5]. CRIS-
PR genes are typically associated with a group of so-called CRISPR-associated (Cas) 
genes, which are both involved in the acquisition of new spacers (i.e. the acquisition 
of new immunity after encounters with pathogens), as well as with expression of im-
munity [6,7]. Most bacteria harboring CRISPR-Cas systems share characteristic cas 
genes (typically cas1-cas6) [8], which are complemented by additional, less widely 
distributed cas genes [9]. Expression of immunity is always based on the transcrip-
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tion of the CRISPR clusters into so-called pre-crRNA, which 
is subsequently cleaved by RNA endonucleases into crRNAs, 
which provide immunity against individual pathogens. The 
crRNAs then serve as guides that hybridize with target DNA 
or RNA to direct the cleavage and thus destruction of the in-
vading nucleic acids [10]. In some ways, CRISPR immunity 
of bacteria is functionally equivalent to adaptive immunity of 
vertebrates. However, CRISPR target selection by annealing 
of complementary nucleic acids is a much more predictable 
process than the interaction of an antibody or B- or T-cell re-
ceptor with a peptide epitope. Therefore, clonal selection is not 
necessary for CRISPR immunity. At the level of bacterial com-
munities, however, bacteria that express “useful” immunity 
against a pathogen may be selected, in a process reminiscent of 
clonal selection in vertebrate adaptive immunity. In contrast to 
vertebrate adaptive immunity, which is not heritable, bacterial 
adaptive immunity is heritable at the level of cells. At the level 
of bacterial communities, CRISPR immunity may also spread 
by horizontal gene transfer (as evidenced by the “sparse” dis-
tribution of CRISPR systems across bacterial species), even 
though the CRISPR systems work of course against horizontal 
gene transfer, at least at the level of populations [11].
CLASSIFICATION OF CRISPR SYSTEMS
A recent review distinguishes two major classes of CRISPR 
systems, according to the type of effector nuclease [12,13]. In 
the class 2 systems, the effector nuclease is a monomer and 
consists of a single polypeptide chain. This class is further sub-
divided into the types II and V, and VI. The type II CRISPR 
systems have a Cas9 endonuclease. This endonuclease has two 
separate catalytic domains belonging to the RuvC and HNH 
catalytic groups. The HNH domain cuts the crRNA bound 
target strand, the RuvC domain the non-target strand [14]. 
Type V systems have a Cpf1, C2c1 or C2c3 type endonucle-
ase, which shares both homology and analogy with Cas9 type 
endonucleases [13]. Type VI endonucleases differ from type II 
and type V endonucleases in that no RuvC motifs have been 
detected, and are still largely uncharacterized. Until very re-
cently, both type II and type V enzymes were considered to be 
exclusively DNA endonucleases. However, very recent work 
has shown that Cpf1 is also involved in processing precursor 
RNA, using an active site not implicated in DNA cleavage [15]. 
In contrast to the class 2 effector endonucleases, class 1 effector 
endonucleases are multi-subunit protein complexes. They can 
be further classified into type I, type III and type IV, with char-
acteristic signature genes (cas3 for type I, cas10 for type III). In 
type I complexes, a Cascade (or Cascade like) protein complex 
selects the target, and then recruits the Cas3 helicase/endonu-
clease, which cleaves target DNA processively [16,17]. Type III 
complexes can target DNA and RNA [18-23], relying on inde-
pendent active sites in the complexes. Type IV endonucleases 
are still poorly studied. In this review, we focus on the recent 
structures of type II and type V CRISPR effector nucleases, 
which have been the focus of intense research activity due to 
their applications in genome editing.
So far, structures are available for Cas9 from Streptococcus 
pyogenes (SpCas9, PDB-accessions 5FW1, 5B2R, 5B2S, 5B2T, 
5F9R, 5FQ5, 4ZT0, 4ZT9, 4UN3, 4UN4, 4UN5, 4OO8, 4CMP, 
4CMQ) [24-29], Francisella novicida (FnCas9, PDB-accessions 
5B2O, 5B2P, 5B2Q) [30], Actinomyces naeslundii (AnaCas9, 
PDB-accessions 4OGC, 4OGE) [29] and Staphylococcus aureus 
(SaCas9, PDB-accessions 5FW1, 5AXW, 5CZZ) [31]. Crystal 
structures include structures of Cas9 alone [29], Cas9 in com-
plex with single guide RNA (sgRNA, a fusion of crRNA and 
tracrRNA) [32], Cas9 with a DNA-RNA duplex [28], and a 
large number of structures of Cas9 with the R-loop that can 
form in the presence of both double stranded target DNA and 
sgRNA. Very recently, a crystal structure has been recruited 
which includes not only the double-stranded region of target 
DNA from the PAM sequence onwards and the sgRNA, but 
also a long region of single-stranded DNA representing the 
non-target DNA strand. For Cpf1, crystal structures of the pro-
tein from Lachnospiraceae bacterium ND2006 (LbCpf1, PDB-ac-
cession 5ID6) [33] and from an Acidaminococcus sp. (AsCpf1, 
PDB-accession 5B43) [34] have been published very recently.
Both Cas9 and Cpf1 proteins are complicated, multi-do-
main proteins. In this review, we will start from the nucleic 
acid structures, and then proceed to the structures of the pro-
teins, which have evolved to interact with these structures.
AN R-LOOP STRUCTURE AT THE CORE OF 
THE GENE TARGETING COMPLEXES
The core structural motif of active Cas9 or Cpf1 complexes 
with substrates is the R-loop, which consists of an RNA-DNA 
duplex and displaced single DNA strand (Fig. 2A). In the con-
text of Cas9 or Cpf1 complexes, the RNA strand of the R-loop 
is the spacer fragment of crRNA. The DNA strand that hybrid-
izes with the crRNA strand is known as the target strand (tsD-
Figure 1. Overview of CRISPR-Cas adaptive immune system. Depicted are the 
spacer acquisition from invading nucleic acids, the CRISPR-Cas expression and 
crRNA maturation (RNAses involved not shown), and CRISPR interference by 
crRNA-guided surveillance. The figure has been adapted from Jiang and Doudna 
[68].
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NA). Its sequence is complementary to the crRNA sequence. 
The DNA strand that is unpaired in the R-loop region is known 
as the non-target strand (ntsDNA). The unpaired region is the 
protospacer region, with a base sequence identical to the se-
quence of the crRNA spacer fragment (except of course for the 
uracil in RNA versus thymine in DNA difference). At the 5’- 
and 3’-ends, a switch-over point marks the transition from the 
RNA-DNA duplex to the DNA-DNA duplex. Protospacer ad-
jacent motifs (PAMs) are found next to protospacers in DNA 
substrates, but not next to spacers in CRISPR clusters [5]. The 
requirement for a PAM in a substrate makes it possible for the 
effector endonucleases to distinguish between substrates and 
the CRISPR cluster, preventing auto-destruction of CRISPR ar-
rays. In the complexes with Cas9 or Cpf1 proteins, the PAM re-
gions are located in regions of double stranded DNA, just ad-
jacent to the switch points, either upstream or downstream of 
the R-loop region (“upstream” and “downstream” are defined 
based on the direction of crRNA from 5’end to 3’end) (Fig. 2B, 
2C). Irrespective of their location upstream or downstream of 
the R-loop region, PAM sequences always refer to the non-tar-
get strand. For downstream PAMs, the first nucleotide of PAM 
is also the first nucleotide of DNA-DNA Watson-Crick pairing. 
For upstream PAMs, the last nucleotide of the PAM is also the 
last nucleotide of DNA-DNA duplex.
HANDLES ON THE crRNA IN THE 
GENE TARGETING COMPLEXES
The crRNA spacer region is of arbitrary sequence, Cas9 and 
Cpf1 proteins make only sequence unspecific interactions with 
the phosphodiester backbone (Fig. 3), but no specific interac-
tions with the DNA bases. Sequence specific contacts defining 
the register of protein-nucleic acid interactions occur in the re-
peat regions, but not the spacer regions of the crRNA.
Cpf1 bound crRNAs contain repeat-derived regions up-
stream of the spacer, which fold into 5’ stem loops. The Lb- Cpf1 bound crRNA indeed forms a simple stem loop. Non-ca-
nonical interactions between nucleobases occur at the base of 
the stem (where RNA-RNA base pairing ends). For AsCpf1, 
the expected stem loop is also present, but because the most 
5’-nucleotides interact with the stem loop, the 5’-handle is 
better described as a pseudoknot.
Cas9 bound crRNAs are anchored at least in part indirect-
ly, by base pairing interactions between the “repeat” of the 
crRNA and the (mostly) complementary “anti-repeat” of the 
trans-encoded crRNA (tracrRNA) [35]. Cas9 interacts with the 
repeat anti-repeat duplex, as well as with the 3’-handle of the 
tracrRNA downstream of the anti-repeat. Jinek and colleagues 
have shown that both the repeat and anti-repeat regions can be 
truncated (on the 3’-side of the repeat and the 5’-side of the an-
ti-repeat), and that the newly generated ends can be connected 
by a tetraloop, leading to a sgRNA, which functionally replac-
es the duplex of crRNA and tracrRNA [36]. Due to its more 
compact nature, sgRNA has been used instead of crRNA tra-
crRNA combinations in all reported crystal structures to date.
Crystallographic data confirm that the repeat anti-repeat 
regions form mostly base paired duplexes, except for a bulge 
roughly in the middle of the repeat anti-repeat double helix. 
In the bulge region, non-canonical interactions, for example 
between a nucleobase and the phosphodiester backbone are 
Figure 2. R-loops. A) Strand nomenclature of R-loops. B) Cas9 and C) Cpf1 crR-
NA and tracrRNA system, adapted from [32,34]. tracrRNA is displayed in short 
form for simplification. The color code of this figure applies to all other figures as 
well, unless otherwise stated.
Figure 3. crRNA binding. A) SpCas9 binding of crRNA. Numbering as in PDB 
ID 4ZTO. The ntsDNA has been truncated (dashed line) for clarity. B) AsCpf1 
binding of crRNA. Numbering as in PDB ID 5B43. Figure prepared in PyMol.
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observed. Moreover, several bases are flipped and thus pro-
vide “handles” for Cas9 to “hold onto” and help define the 
register of binding of the repeat anti-repeat region. In the Cas9 
complexes, the tracrRNA extends beyond the anti-repeat re-
gion and forms a series of stem-loops (numbered according to 
their position in the tracrRNA sequence from the anti-repeat 
towards the 3’-end). The degree of conservation of the stem 
loops decreases towards the 3’-end. Stem loop 1 is partially 
conserved between S. pyogenes and S. aureus, but not F. novici-
da. Three stem loops are present in S. pyogenes. S. aureus tracrR-
NA or sgRNA have two 3’-stem loops, but for crystallization 
purposes, the RNA was truncated after stem loop 1. For F. novi-
cida, two stem loops are detected, which are both dissimilar in 
sequence to the ones in S. pyogenes. The overall shape of stem 
loop 1 and also its orientation with respect to the repeat an-
ti-repeat duplex are largely conserved, and together with the 
repeat anti-repeat duplex, stem loop 1 forms a core structural 
motif in the complexes. The other stem loops are structurally 
diverse. Variations in stem loop sequence, structure and over-
all shape explain why tracrRNAs or sgRNAs tend to be non-in-
terchangeable except between closely related species [37].
At first sight, the indirect anchoring of the crRNA by tracrR-
NA in the Cas9 complexes seems unnecessary complicated by 
comparison with the simple attachment of a 5’-handle to the 
crRNAs in the Cpf1 complexes. However, at second sight, the 
indirect mode of anchoring the crRNA may have its advan-
tages. First, we note that the repeat anti-repeat region of the 
crRNA tracrRNA duplex (more precisely the part that is pre-
served in the sgRNA) interacts with Cas9 proteins, providing 
an additional handle in addition to the 3’-end of the sgRNA 
or tracrRNA. We also note that in S. pyogenes, the combined 
length of the repeat of crRNA and tracrRNA is approximate-
ly 100 nucleotides, and that the (truncated) sgRNAs for Cas9 
from this species still contain about 80 nucleotides of non-spac-
er sequence. If entire sgRNAs were derived from CRISPR re-
peats, these would have to be at least 80 and perhaps even 100 
nucleotides long, compared to actual CRISPR repeat lengths 
between 20 and 50 nucleotides [38]. Repeats are generally asso-
ciated with genetic instability. In CRISPR systems, some of the 
instability is desirable, because it makes it possible to eliminate 
spacers (and associated repeats) that have lost their biological 
usefulness [39]. One may speculate that actually observed re-
peat lengths suffice to keep CRISPR clusters adaptable, and 
that additional genetic instability associated with longer re-
peats may be undesirable. To our knowledge, this explanation 
has not been tested, but the idea has some support from the 
distribution of spacer lengths across CRISPR systems from a 
wide variety of species.
COMPLETE NUCLEIC ACID STRUCTURES IN 
Cas9 AND Cpf1 TARGETING COMPLEXES
The nucleic acid structures in Cas9 and Cpf1 complexes are 
rather different from each other. Leaving aside the non-target 
DNA strand, which is present in all cases, but has so far been 
tracked crystallographically only in the Cas9 complex [26], 
the nucleic acid arrangement in the Cpf1 complex can be de-
scribed as a three-arm structure, with double stranded DNA 
(with PAM) forming one arm, the crRNA-DNA heteroduplex 
forming another arm, and finally the 5’-handle of the crRNA 
forming the third arm. In Cas9 complexes, a four armed struc-
ture is formed. The arms are the sgRNA-DNA heteroduplex, 
the repeat anti-repeat RNA duplex, the (substrate) DNA-DNA 
duplex, and the 3’-handle of the tracrRNA (Fig. 4).
In the Cas9 complexes, the sgRNA in the spacer and repeat 
region follows roughly the trajectory that would be expected 
for it in an A-form duplex (Fig. 3A). As a result the guide-tar-
get DNA-RNA heteroduplex and the repeat anti-repeat het-
eroduplex are approximately co-linear (Fig. 4A). The target 
DNA strand changes direction drastically at the switchpoint. 
Therefore the duplex with the non-target DNA strand and 
the duplex with the spacer region of sgRNA are almost per-
pendicular to each other. The direction of the 3’-handle is not 
conserved between different Cas9 complexes. In the SpCas9 
complex, this region runs approximately parallel to the DNA 
duplex, whereas it runs approximately perpendicular to it 
in the FnCas9 complex. In the Cpf1 complexes, the least per-
turbed strand is the DNA target strand. Therefore, the DNA 
duplex region (with PAM) and the RNA-DNA heteroduplex 
are approximately collinear. The 5’-handle runs approximate-
ly perpendicular to this direction. Thus, the nucleic acid struc-
tures that need to be created and processed by Cas9 and Cpf1 
proteins are quite different, and hence it is no surprise that also 
the proteins themselves are quite different from each other.
Cas9 AND Cpf1 DOMAIN ORGANIZATION
Cas9 proteins are relatively large, monomeric multi-do-
main proteins. Their size varies considerably, in the range from 
about 900 to about 1600 amino acids. SaCas9 with only 1053 
amino acids belongs to the “small” Cas9 proteins. FnCas9 with 
1629 amino acid is a “large” Cas9. The prototypical SpCas9, 
which is currently used in most genome engineering applica-
tions, consists of 1368 amino acids and thus falls in terms of 
size somewhere midway between the “small” and “large” 
Cas9 proteins. All Cas9 proteins studied to date have a bi-
lobed architecture. The two lobes are known as the recognition 
(REC, no relation to helicases) and nuclease (NUC) lobes [28] 
(Fig. 5A).
In the prototypical SpCas9, the REC lobe itself is built from 
a long α-helix, termed the bridge helix (BH), and three subdo-
mains, termed REC1, REC2 and REC3. REC1 is directly down-
stream of the BH, REC2 is an “insertion” in the REC1 domain. 
REC3 is downstream of REC1, and was included in REC1 in 
some early descriptions of the structure. The NUC lobe con-
sists of a RuvC-like domain, and HNH like-domain, a wedge 
domain (WED, included in an adjacent domain in the original 
description of the structure [28]), and the PAM-interacting do-
main (PI). The WED domain has been given its name, because 
it is wedged between the repeat anti-repeat RNA duplex and 
the target strand non-target strand DNA duplex in the crystal 
structures. The PAM interacting domain, as its name suggests, 
is responsible for PAM sequence recognition. In some de-
scriptions, this domain is further subdivided into a topoisom-
erase-homology domain (TOPO) and a C-terminal domain 
(CTD) (Fig. 5A). Biochemical experiments have demonstrated 
that the RuvC and HNH-domains cleave the non-target and 
target strands, respectively [14]. The entire SpCas9 protein is 
best thought as a very elaborate version of a RuvC like domain 
(Fig. 5B, C). The HNH domain and the entire REC lobe are in-
sertions in the RuvC domain, the WED and PI domains are 
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downstream of the RuvC domain. The “fragmentation” of the 
RuvC domain in Cas9 suggests that this domain is the “origi-
nal” scaffold, which has then be elaborated by the insertion of 
the REC lobe (itself comprising the BH and REC1, REC2 and 
REC3 domains) and the HNH domain, as well as by the addi-
tion of the phosphate-lock loop (PLL, a short but functionally 
important part of the structure), and of the WED and PI do-
mains at the C-terminus.
The smaller SaCas9 is generally similar to the architecture 
of SpCas9, but there are several contractions. First, the recogni-
tion lobe spans only 385 residues, compared to 658 residues for 
the recognition lobe of SpCas9. A major contraction is also seen 
in the PI, where the SaCas9 CTD comprises 85 residues, com-
pared to 168 amino acids in the SpCas9. On the other hand, the 
WED domain, which is so compact in SpCas9 that it was not 
originally considered as an independent domain, is larger in 
SaCas9 compared to SpCas9.
The large FnCas9 also has essentially the same conserved 
architecture, but now there are mostly additional insertions 
compared to the “reference” SpCas9. The REC lobe of Fn-
Cas9 is expanded (775 residues) compared to the REC lobe of 
SpCas9 (658 residues), and also BH, REC1, REC2 and REC3 
composition, with REC2 inserted into REC1. However, parts 
of the REC lobe of FnCas9 are structurally unique and have 
no counterparts in SpCas9, and surprisingly, the FnCas9 REC2 
domain adopts a new fold unrelated to its counterpart in Sp-
Cas9. The NUC lobe of FnCas9 is similar in organization to the 
NUC lobes of the other Cas9 proteins, but the WED domain is 
larger than in SpCas9 or SaCas9.
Cpf1 proteins are superficially similar in architecture to 
Cas9 proteins, but most of the similarity results from anal-
ogy rather than homology, as already predicted before the 
first Cpf1 crystal structures were solved [13] (Fig. 5A). As 
the LbCpf1 [33] and AsCpf1 [34] were solved and interpret-
ed independently of each other, there is no unified nomen-
clature for the domains in Cpf1 proteins yet. In fact, due to 
the timing of crystal structures, and the involvement of dif-
ferent laboratories, the unfortunate situation has now arisen 
that domains with perceived similar or analogous functions, 
but no homology carry the same labels, whereas domains 
that are clearly homologous, but were studied by different 
groups, carry different labels. We suspect that the nomen-
clature of Yamano and colleagues (who had DNA in their 
complex to facilitate interpretation) [34] will prevail and 
therefore use it preferentially.
The AsCpf1 protein has been described as bi-lobed by 
the authors of the crystal structure [34]. By analogy with 
Cas9, the two lobes have been termed the REC and NUC 
lobes (Fig. 5A). The REC lobe consists of REC1 and REC2 
domains, which have similar functions as their counterparts 
in Cas9 proteins, but are not similar in sequence or struc-
Figure 4. R-loops cartoon representation, and arms assignment. A) Four arms 
present in the SpCas9 structure (PDB ID 5F9R). B) Three arms present in As-
Cpf1 structure (5B43). The orientation was chosen so that the strands of the sgR-
NA-DNA heteroduplex overlap. Figure prepared in PyMol.
Figure 5. Domain organization, topology and structural aspects of Cas9 and 
Cpf1. A) 1D domain organization of SpCas9 and AsCpf1 and annotation of the 
respective proteins lobes, REC and NUC. B) Structure (left panel) and topolo-
gy arrangements (right panel) of RuvC (PDB ID 4LD0). C) Structure (left panel) 
and topology arrangements (right panel) of SpCas9 (PDB ID 5F9R). Secondary 
structure elements inserted on the RuvC fold (blue) are in light brown color, and 
domain insertion represented by rods/square-arrows in olive color. D) Structure 
(left panel) and topology arrangements (right panel) of LbCpf1 (PDB ID 5ID6). 
Secondary structure elements inserted on the RuvC fold (blue) are in light brown 
color, and domain insertion represented by rods/square-arrows in olive color. 
Structural panels prepared with PyMol.
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ture (except for strong overrepresentation of α-helices in 
the fold). The NUC lobe consists of a RuvC domain, and 
at least three additional domains that are not homologous 
to domains in Cas9. Based on similar roles in the complex-
es, two of these domains have been called the WED and PI 
domains. The third domain may be involved in DNA cleav-
age and has been called the Nuc domain (not to be con-
fused with the NUC lobe, which contains the Nuc domain 
among others). There is no HNH domain in Cpf1 proteins. 
Biochemical data show that inactivation of the RuvC active 
site in Cpf1proteins blocks cleavage of both DNA strands, 
and this finding was originally interpreted as evidence that 
the RuvC domain cleaves both strands [40]. In the AsCpf1 
structure, the RuvC domain is not well positioned to cleave 
the target DNA strand, but the Nuc domain would be well 
positioned for this task, prompting the hypothesis that the 
Nuc domain carries out this cleavage step [34]. Howev-
er, the Nuc domain does not appear to be homologous to 
known nucleases, and the active site has not yet been iden-
tified. Moreover, the mechanistic basis for RuvC control of 
Nuc activity remains enigmatic. Therefore, the assignment 
of catalytic activity to the Nuc domain remains tentative.
The LbCpf1 has a similar structure, but the nomenclature 
is different [33]. The authors of the structure noticed simi-
larity between the LbCpf1 counterpart of the WED domain 
and a known RNA binding protein, termed small protein 
B, and termed the domain oligonucleotide-binding domain 
(OBD). The looped-out helical domain (LHD) in LbCpf1 cor-
responds to the PI in AsCpf1, but was not identified as PAM 
interacting, because the crystallized LbCpf1 complex con-
tains only crRNA, but not target DNA. The helix-loop-helix 
region in LbCpf1 comprises the BH (basic helix), which is 
interacting with the crRNA. The counterpart of the Nuc do-
main in AsCpf1 is the “unknown” (UK) domain of LbCpf1, 
to which the authors of the crystal structure did not ascribe 
nuclease activity (but also did not exclude it).
PROBABLE EVOLUTION OF Cas9 AND Cpf1 PROTEINS 
FROM A HOLLIDAY JUNCTION RESOLVASE
The presence of the RuvC domain in both Cas9 and Cpf1 
proteins and the large number of insertions in this domain 
(only the WED domain in Cpf1 is similarly “fragmented”) sug-
gests that both Cas9 and Cpf1 proteins have evolved from a 
RuvC-like Holliday junction resolvase (Fig. 5B, C, D). Superfi-
cially, this idea gains additional support from the observation 
that both RuvC proteins and CRISPR proteins interact with 
nucleic acid structures that contain single and double stranded 
regions, as well as cross-over regions between them. Surpris-
ingly, detailed structural comparisons show that the nucleic 
acid binding modes of the RuvC and Cas9 complexes are not 
closely related. Despite this difference, it is likely that both 
Cas9 and Cpf proteins have evolved from RuvC-type Holliday 
junction resolvases or closely related transposases [12]. In fact, 
a careful analysis of Cas9 and Cpf1 sequences suggests that the 
Cas9 and Cpf1 families have evolved from different families of 
transposon encoded Tnp proteins, containing either only RuvC 
and HNH or only RuvC domains. An “early” split of Cas9 and 
Cpf1 proteins is also suggested by the observation that Cpf1 
loci contain Cas1, Cas2 and Cas4 proteins more closely related 
to those in type I than type II CRISPR systems [40,41].
ROLE OF THE PI IN PAM READOUT
Cas9 and Cpf1 both read DNA sequence by protein-DNA 
interactions (with the PAM) and by nucleic acid hybridiza-
tion (between target strand and crRNA). Probing DNA for 
the presence of the PAM consensus is possible in the context 
of double stranded DNA, whereas sequence comparisons 
by hybridization require local DNA melting. For efficient 
scrutiny of long DNA molecules, one can therefore expect 
that the scan for PAM sequences should be the first step in 
target recognition. Experiments confirm this expectation 
[27,42], and crystal structures further demonstrate that the 
PAM is indeed read out in the context of double strand-
ed DNA [27]. Conceptually, detection of PAM sequences 
is therefore similar to the detection of the recognition se-
quence by restriction endonucleases, and one can expect 
typical motifs for the binding of bases or base pairs, such as 
arginine guanine interactions and interactions between ade-
nines and glutamine residues. In some cases, the PAMs are 
partially degenerate, and for example purines (R) or pyrim-
idines (Y) in one strand, but not a specific base, are required 
in a given position. From prior experience for amino acid 
based readout of DNA sequence (as opposed to nucleic acid 
based readout) one may then expect two possible strategies. 
First water mediated hydrogen bonds may replace direct 
hydrogen bonds. As water may act as a donor or acceptor 
for two hydrogen bonds each, water mediation of hydrogen 
bonds can select for either a hydrogen bond donor or accep-
tor. Second, contacts may be mediated by asparagine or glu-
tamine residues, which can serve as hydrogen bond donors 
or acceptors (of similar shape), depending on the side chain 
rotamer. Inspection of interactions between PAM interact-
ing domains and PAMs in the available crystal structures 
shows that sequence specificity for PAMs indeed operates 
based on the expected biophysical principles.
Cas9 PAM interactions have been studied for several 
years now, starting from the elucidation of the first Cas9 
protein in complex with an R-loop comprising the PAM re-
gion [27]. For both SpCas9 and FnCas9, the PAM sequence 
is NGG. Crystal structures show that the PAM guanines 
engage in bidentate hydrogen bonding interactions with 
arginine residues [27,30] (Fig. 6A). For SaCas9, the PAM is 
NNGRRT (where R stands for purine, i.e. either A or G). The 
G in the PAM is equivalent to the “last” G in the NGG PAM 
and interacts via its Hoogsteen edge with the guanidino 
group of an arginine residue. Selection for the purines (RR) 
and against pyrimidines (YY) downstream of the G is based 
on interactions between the bases and asparagine residues, 
or water mediated hydrogen bonds [31], in agreement with 
the principles outlined for semi-degenerate recognition of 
DNA bases outlined above. The PAMs for proteins in the 
Cas9 family all appear related, and some of the interactions 
between the proteins and the conserved PAM DNA bases 
are very similar and probably homologous. However, there 
are also proteins in the Cas9 family, as noted by Anders and 
colleagues, which have very different PAMs. For example, 
the PAM for Cas9 from Lactobacillus buchneri is NAAAA [43], 
The loop in the PAM interacting domain that anchors amino 
acids that make direct contacts has a very different sequence 
in the L. buchneri Cas9 (QLQ) compared to S. pyogenes Cas9 
(RYR) [24]. However, a crystal structure that elucidates the 
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detailed interactions between Lactobacillus buchneri Cas9 
and the PAM for this species has not yet been solved.
As PAMs constrain uses of RNA guided endonucleases, 
many efforts have been made to generate Cas9 proteins which 
accept very generic PAMs, or to make Cas9 variants that recog-
nize novel PAM sequences. The task is not easy, because Cas9 
activity goes down when PAM binding is poor and because 
it is hard to find protein motifs that interact tightly with very 
short stretches of DNA. Nevertheless, some successes have 
already been achieved, in some cases by design (the FnCas9 
PAM specificity has been altered from NGG to YG) [30], and in 
other cases by a combination of rational design and selection 
strategies to identify useful protein variants from large and 
diverse pools of candidate variants. SpCas9 variants (“VQR”, 
“EQR” and “VRER”) have been found that are compatible 
with NGAN, NGNG and NGCG PAMs [44], and very recent 
crystal structures have confirmed the expected structural ex-
planations for the altered specificities [24,30].
Cpf1 PAM interactions could not be predicted based on 
Cas9 PAM interactions, because the PAM interacting domains 
are not homologous between Cpf1 and Cas9 proteins (as sug-
gested not only by sequence and structure comparisons, but 
also by the location of the PAM upstream and downstream of 
the heteroduplex region for Cpf1 and Cas9, respectively). The 
very recent crystal structure of AsCpf1 offers a glimpse on 
how Cpf1 proteins interact with PAM regions [34] (Fig. 6B). 
The PAM for AsCpf1 is TTTN, the AT rich duplex with this 
sequence assumes a distorted DNA structure with very nar-
row minor groove. Interactions are from both the major and 
minor groove sides. Sequence specificity appears to be part-
ly based on hydrogen bonding interactions, and partly also 
on shape selection (e.g. a guanine NH2 group in the central 
minor groove would clash with a lysine of AsCpf1, thymine 
methyl groups occupying a unique position on the outer ma-
jor groove side not accessible to other bases stack very favor-
ably). The LbCpf1 crystal structure contains only crRNA, but 
not target DNA, and is therefore not informative about PAM 
interactions (the LbCpf1 PAM is complicated and may be ap-
proximately described as YYYN, where Y stands for T or C, 
and T is preferred over C in all three positions [40]).
ROLE OF THE PLL AND BH IN DNA 
STRAND SEPARATION
Adjacent to the PAM, DNA strands have to be sep-
arated for interaction with crRNA (or sgRNA), in a se-
quence-non-specific manner. In the case of R-loop com-
plexes with Cas9, the phosphodiester group linking the last 
residue of the strand-separated region of DNA to the first 
residue in double stranded DNA seems to play a key role. 
This phosphate group engages in several hydrogen bond-
ing interactions with amino acids of a loop in Cas9, which 
has therefore been termed the “phosphate lock” loop [27]. 
The lock loop acts to fix the DNA backbone in such a man-
ner that the bases adjacent to the switch-point (between 
DNA-DNA duplex and DNA-RNA heteroduplex) point 
essentially in opposite directions, without much affecting 
the “trajectory” of the phosphodiester backbone (Fig. 7). 
This drastic deformation of the DNA target strand assures 
that the bases in the protospacer complementary region are 
fully accessible for interactions with crRNA (or sgRNA). 
Mutations to amino acids of Cas9 involved in the “locking” 
reduce or abolish Cas9 activity, especially when mutations 
occur in combination [27]. In FnCas9 and SaCas9, the ami-
no acids of the lock loop differ from those in SpCas9, but 
because the interactions are between phosphate and main-
chain, the mode of action of the lock-loop is nonetheless 
conserved [30,31].
Both Cas9 and Cpf1 proteins do not have known bind-
ing sites for ATP or other molecules, which could serve as 
a source of energy, in order to drive the separation of DNA 
strands. Thermodynamics suggests that such a source of 
energy is also not required. RNA-DNA hybrids are typical-
ly more stable than DNA-DNA hybrids, but differences are 
sequence dependent, and in rare cases, the relationship can 
be reversed [45]. Whether relative RNA-DNA hybrid ver-
sus DNA-DNA stability affects the efficacy of targeting does 
not appear to have been addressed in a systematic manner. 
However, structures have already shown that Cas9 and Cpf1 
proteins facilitate RNA-DNA hybrid formation by pre-bind-
ing the crRNA in the spacer region in an A-like conformation 
that is typical for RNA-DNA duplexes, thus facilitating their 
formation (Fig. 3). The interactions anchoring the phosphodi-
ester backbone of the spacer region of the crRNA or sgRNA 
are sequence non-specific and predominantly involve the 
Figure 6. PAM recognition. A) Structural details for the SpCas9 protein. Number-
ing as in PDB ID 5F9R. B) Structural details for the AsCpf1 protein. Numbering as 
PDB ID 5B43. Figure prepared in PyMol.
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phosphates in the RNA backbone and basic residues, typical-
ly arginine residues in the BH.
DNA CLEAVAGE
Both Cas9 and Cpf1 cleave the target DNA strand in the 
heteroduplex region and the non-target strand in the region 
where it is single stranded. In all cases, cleavages occur on 
the “downstream” side of the R-loop, close to the PAM for 
Cas9 and distant to the PAM for Cpf1. Cas9 makes blunt 
and cuts, three nucleotides away from the PAM [14]. Cpf1 
cleaves the non-target strand further upstream than the tar-
get strand, resulting in staggered DNA ends, with four to 
five nucleotide 5’-overhangs [40].
For Cas9, the involvement of HNH and RuvC endonu-
clease domains in DNA cleavage is certain. For Cpf1, the 
involvement of the RuvC domain in DNA cleavage is also 
undoubted, but the suggested direct catalytic activity of 
the Nuc domain is still tentative and not fully understood. 
Therefore, we will focus here only on the catalytic activity 
of the RuvC and HNH domains. Both catalyze phosphodi-
ester hydrolysis reactions that lead to 5’-phosphates and 
free 3’-OH groups. For catalysis, a water molecule has to 
positioned and activated for inline attack on the phosphorus 
atom of the phosphate. Moreover, the leaving group (the fu-
ture 3’-OH) has to be activated.
The most conserved function in DNA nuclease cataly-
sis is the activation of the leaving group [46]. In RuvC (or 
RNAseH) and HNH nucleases it occurs by direct contact of 
a divalent metal cation with the leaving group oxygen atom 
(effectively “acidifying” this group). Positioning and activa-
tion of the water (or hydroxide) nucleophile is achieved in 
more diverse manner. In RuvC type nucleases, which use 
a two metal ion mechanism [46], the activation and posi-
tioning of the nucleophile involves a second divalent metal 
cation, which is distinct from the one that promotes the de-
parture of the leaving group. In contrast, HNH endonucle-
ases use amino acid based catalysis for this step [47] (Fig. 8).
TARGET STRAND CLEAVAGE
Biochemical experiments indicate that the target strand 
in the RNA-DNA duplex is cleaved by the HNH domain of 
Figure 7. Phosphate-lock loop and base flip. A) Scheme of the phosphate-look 
loop mechanism and initial steep of RNA-DNA heteroduplex formation for Cas9 
proteins. B) Structural detail for the SpCas9 protein. Numbering as in PDB ID 
4UN3. C) Structural detail for the AsCpf1 protein. Numbering as in PDB ID 5B43. 
Panels B and C prepared in PyMol.
Figure 8. Nuclease catalytic mechanism. A) HNH one metal catalytic center. B) 
RuvC two metal catalytic center. Arrows indicate the inline attack of the activated 
water on the phosphorus atom of the phosphate.
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Cas9 [14]. The term HNH for this group of nucleases high-
lights a pattern of conserved residues in then known mem-
bers of this protein family. In the meantime, the family has 
grown, and it has become clear that only the first “H” of the 
HNH designation is indeed a conserved histidine, where-
as the “N” in the HNH designation is frequently not con-
served, and the second “H” of the HNH designation may 
be replaced by an asparagine. The HNH group of nucleases 
is therefore better described by the alternative designation 
ββα-Me (where Me stands for metal cation) nuclease family, 
which refers to a conserved structural motif that is indeed 
present in all family members. The two β-strands run anti-
parallel to each other and frequently connected directly to 
form a hairpin. The α-helix follows immediately after the 
second β-strand. A histidine, anchored in the first β-strand 
(the first H in the HNH designation) serves as the general 
base to activate the nucleophilic water. An aspartate residue 
directly upstream and a histidine or asparagine residue in 
the α-helix anchor the divalent cation, typically Mg2+ [47] 
(Fig. 8A).
The ββα motif is present in SpCas9. Sequence compar-
isons suggest Asp839 and His840 (in the “first” β-strand) 
and Asn863 (in the α-helix) as key residues in the active site. 
Mutations of His840 or Asn863 to alanine convert SpCas9 
into a nickase, supporting a role of these residues in catal-
ysis [28]. However, a puzzle remains: in multiple crystal 
structures of SpCas9, Asn863 points away, not towards the 
predicted location of the bound metal ion, and in this con-
formation clearly cannot take part in anchoring a metal ion. 
Moreover, an arginine residue (Arg864) points towards the 
predicted metal ion location, so that the guanidino group 
comes close to the location of the metal ion, suggesting that 
it may functionally replace the metal ion. Alternatively, and 
perhaps more probably, the “unproductive” orientation of 
Asn863 may be due to limitations of the crystallographic ex-
periments. First, inactivating variants of Cas9 were used in 
most crystallization experiments. Second, the HNH domain 
in most structures is distant from the scissile phosphodi-
ester bond that it should cleave, and it is not uncommon 
for nuclease active sites to be disordered in the absence of 
substrate. Third, Mg2+ ions, which must have been present 
in the expression system, may have been lost during purifi-
cation, leading to a loss of the catalytically competent state. 
Finally, the limited resolution of the crystallographic data, 
which is typical for such large structures, makes detailed in-
terpretation of the electron density difficult.
The knowledge (rather than structure) based assignment 
of active site residues is also supported by conservation 
(see Fig. 6 of ref [31]]). The equivalent residues to Asp839 
and His840 and Asn863 in SpCas9 are Asp556, His557 and 
Asn580 in SaCas9, Asp581, His582, and Asn606 in AnCas9. 
In the SaCas9 structure, the Asn580 has been mutated, but 
AnCas9, Asn606 is present, and points in the expected direc-
tion, also suggesting a canonical HNH-type mechanism for 
Cas9 nucleases.
For Cpf1 proteins, there is currently some uncertain-
ty about the cleavage of the target DNA strand. It may be 
cleaved either by the RuvC domain, as suggested by the 
biochemical data [40], or it may be cleaved by the Nuc do-
main, as suggested by the AsCpf1 crystal structure [34]. As 
the Nuc domain is only close, but not directly bound to sub-
strate DNA-RNA hybrid, a catalytic mechanism cannot be 
inferred from the crystal structure. As the Nuc domain is 
not similar to better characterized nucleases, the mechanism 
cannot be inferred by homology either, and remains to be 
elucidated.
NON-TARGET STRAND CLEAVAGE
Biochemical experiments indicate that the non-target 
strand of DNA is cleaved by the RuvC domain of Cas9 and 
Cpf1 [14,40]. The RuvC domains belong to a group of nu-
cleases that includes RuvC Holliday junction resolvases, 
RNaseH, RNaseHII, HIV reverse transcriptase, HIV inte-
grase, some transposases, as well as Argonaute proteins 
[48]. All of these enzymes are believed to operate by a two 
metal ion mechanism [46] (Fig. 8B). Both metal ions are be-
lieved to help stabilize the negative charge in the transition 
state (by direct interactions with one of the non-bridging 
phosphate oxygen atoms). One divalent metal cation (of-
ten termed metal cation A) is also involved in positioning 
and activating the nucleophile, the other metal cation (of-
ten termed metal cation B) in promoting the departure of 
the leaving group. Conserved aspartic and glutamic acids 
anchor the metal cations. A strictly conserved aspartate resi-
due, typically the most conserved of the conserved catalytic 
residues, is a direct ligand to both metal ions. In addition, 
metal ions A and B are contacted by one or two acidic resi-
dues, or in some cases also histidine residues.
The putative catalytic residues in the RuvC domain of 
SpCas9 are Asp10, Glu762, His983, and Asp986. This set is 
highly reminiscent of the set of catalytic residues in T. ther-
mophilus RuvC (Asp7, Glu70, His143 and Asp146). The role 
of catalytic residues in the T. thermophilus is itself somewhat 
uncertain (due to lack of metal ions and the limited reso-
lution of this structure), but the likely scenario is that Sp-
Cas9 Asp10 Cas9 is the acidic residue in direct contact to 
both metals A and B, Glu762 anchors metal B, and His983 
and Asp896 anchor metal A. Unfortunately, none of the 
Cas9 structures has two metal ions and sufficient resolution 
to confirm this prediction directly. The FnCas9, solved at 
a resolution of 1.7 Å, has one metal ion (a Ca2+ ion) in the 
active site, presumably occupying the position of metal A, 
and a conserved set of active site residues (Asp11, Glu898, 
His1162, and Asp1165). In SaCas9, the active site residues 
are conserved (Asp10, Glu477, His701 and Asp704), but no 
metal is present.
The putative catalytic residues in the RuvC domain of As-
Cpf1 are Asp908, Glu993 and Asp1263. Based on the order 
in the amino acid sequence, it is likely that Asp908 contacts 
both metals A and B, Asp908 metal B, and Glu993 metal A
CONFORMATIONAL FLEXIBILITY
As multi-domain proteins, Cas9s have substantial confor-
mational flexibility, as initially demonstrated by cryo-elec-
tron microscopy reconstructions of the complex. The data in-
dicated substantial rearrangements between the two major 
lobes of Cas9 between the states of the protein in isolation, 
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the protein bound to RNA only, and the protein bound to 
RNA with DNA substrate (presumably forming the R-loop) 
[29]. Substantial rearrangements were then also demon-
strated by comparing the structure of Cas9 bound to sgRNA 
only (“pre-target”) and bound to sgRNA and DNA (“target 
bound”) (Fig. 9). In particular, parts of the REC lobe and the 
HNH domain were found to change their position drastical-
ly between these states [32]. However, it was also clear that 
even the target bound conformation could not be the produc-
tive one, because the active site of the HNH domain, which 
should cleave the target DNA strand in the heteroduplex 
was found to be far away from the scissile phosphodiester 
bond [28,32]. The first Cas9 structure with HNH domain 
poised to cleave the DNA target strand was obtained when 
a single stranded portion of the non-target DNA strand was 
also included in the crystallization mix [26]. The presence of 
the single stranded region of the non-target strand has very 
little influence on the arrangement of the nucleic acids, but 
it induces a drastic reorientation of the HNH domain. As 
a result, the HNH domain active site comes close the scis-
sile phosphodiester bond that should be cleaved according 
to the biochemical experiments. Moreover, the non-target 
DNA single strand also extends towards the RuvC active 
site, with the scissile phosphodiester bond coming close to 
it. For Cpf1, a crRNA complex of LbCpf1 and a crRNA DNA 
complex of AsCpf1 have been trapped by crystallographic 
methods, but a series of crystal structures of one and the 
same protein in different functional states is not yet avail-
able. Electron microscopy data for LbCpf1 suggest that his 
Cpf1 proteins may be equally flexible as Cas9 proteins [33].
APPLICATIONS OF CRISPR EFFECTOR NUCLEASES
Prior to the advent of CRISPR based genome engineer-
ing, the field was dominated by meganucleases [49], zinc 
finger nucleases (ZFNs) [50], and transcription activa-
tor like nucleases (TALENs) [51]. In all cases, a separate 
protein had to be engineered and validated for every 
target site. In contrast, Cas9 and Cpf1 proteins have the 
advantage that a generic endonuclease together with an 
easily produced RNA could target almost any genomic 
locus of choice (restricted only by the requirement for a 
PAM). Breakthroughs on the way towards genome en-
gineering applications of Cas9 were the demonstration 
that the Cas9 system could work in a heterologous host 
[52], the discovery of tracrRNA [35,53], and its combina-
tion with crRNA into sgRNA [36]. Most importantly, the 
Cas9 endonucleases turned out to operate also in the con-
text of eukaryotic chromatin [54], even though they do 
not encounter chromatin in physiological conditions and 
even though Cas9 activity is inhibited by nucleosomes in 
vitro [55]. Variants of Cas9 are now available that have 
improved specificity [56-58], generate a nick instead of a 
double strand break [59], or lack activity altogether for 
transcriptional control [60,61]. In cell culture, CRISPR 
guide RNA libraries are now available that make it pos-
sible to carry out genome wide loss of function screens, 
which were previously only possible using RNA interfer-
ence [62,63]. CRISPR/Cas9 has also proven to be useful 
for the generation of transgenic animals [64-66] and plants 
[67]. Because Cas9 or Cpf1 based targeted endonucleases 
are relatively cheap and easy to make, the availability of 
these tools has “democratized” genetic engineering and 
is likely to cause a revolution in the biosciences, if it has 
not already done so.
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STRESZCZENIE
Nukleazy efektorowe Cas9 i Cpf1, będące częścią systemu CRISPR typu II i V, są „uniwersalnymi” endonukleazami DNA, które za pomocą 
odpowiedniej sekwencji crRNA lub sgRNA mogą zostać zaprogramowane do przecięcia niemal każdego dwuniciowego DNA w określonym 
miejscu (oflankowanym krótkimi sekwencjami PAM). W niniejszym artykule przeglądowym omówiono bakteryjny system odporności swo-
istej CRISPR jako naturalny kontekst, w którym działają nukleazy Cas9 i Cpf1, i przedstawiono informacje strukturalne dotyczące działania 
tych białek uzyskane w ciągu ostatnich 2-3 lat. Opisano także strukturę „pętli R” zlokalizowanych w rdzeniu kompleksów Cas9 i Cpf1 oraz 
„uchwytów” 5’ i 3’ biorących udział w kotwiczeniu kompleksów kwasów nukleinowych na białkach w sposób niezależny od sekwencji 
docelowej. W artykule omówiono również budowę molekularną białek Cas9 i Cpf1, mechanizm skanowania przez nie dwuniciowego DNA 
w poszukiwaniu sekwencji PAM (ang. protospacer associated motifs), a także sposób rozdzielenia docelowej i niedocelowej nici DNA z 
udziałem pętli fosforanowej (PLL, phosphate loop) i helisy podstawowej (BH, basic helix) oraz formowanie się hybryd złożonych z crRNA lub 
sgRNA i docelowej nici DNA. Ponadto, opisano przyjęty obecnie mechanizm działania domen katalitycznych RuvC i HNH oraz możliwą, a 
jednocześnie wciąż bardzo niepewną, katalityczną rolę domeny Nuc. W końcowej części niniejszego artykułu przeglądowego znajduje się 
natomiast krótkie podsumowanie kluczowych osiągnięć, które zapoczątkowały zastosowanie nukleaz Cas9 i Cpf1 w inżynierii genomowej.
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